Precisely, a hemibody pair addressing CD38 and SLAMF7 redirects T cells against dual antigen-positive myeloma cells in vitro and in vivo, while sparing single antigen-positive bystanders. This evidence concerns the gene SLAMF7 and plasma cell myeloma.